Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
Date: May 20, 2019
Issue #:
1572Summary:
The FDA has approved omadacycline (Nuzyra– Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Antibacterials Avelox Bactrim Cefadroxil Ceftriaxone Cephalexin Clindamycin Dicloxacillin Doxycycline Haemophilus influenzae Levofloxacin Linezolid Moxifloxacin Mycoplasma pneumoniae Nuzyra omadacycline skin and skin struct Source Type: research
More News: Avelox | Bacterial Pneumonia | Bactrim | Cefadroxil | Ceftriaxone | Cephalexin | Clindamycin | Doxycycline | Drugs & Pharmacology | Haemophilus Influenzae (Hib) | Levaquin | Linezolid | Moxifloxacin | Pneumonia | Rocephin | Skin | Tetracycline | Zyvox